| Revenue growth | Q2 +81%, H1 +57% YoY |
|---|---|
| Margins | Q2 EBITDA margin 17.45% (+897bps); H1 16.50% (+894bps) |
| Order book | Rs825 Cr global CDMO mandate (Feb'26) |
| Demand visibility | Longer-duration global programmes; no quantified visibility |
| Management confidence | Confident tone; 'record' earnings stated |
Growth
Q2 EBITDA Rs132 Cr (+273%); H1 EBITDA Rs220 Cr (+243%), PAT Rs145 Cr (+177%). H1 exports Rs654 Cr (+122%).
Outlook
No numeric guidance. Capacity 614 KL to 800 KL expansion 'behind visibility'; no capex amount disclosed.
Risks
No explicit risks stated; lumpy CDMO ramp (Q1 Rs58 Cr vs Q2 Rs253 Cr) and generic pricing/regulatory caveats.
Investor Presentation filed with BSE, NSE: MOREPENLAB. Summary written with AI assistance from the document.
Morepen Laboratories Ltd: key numbers
- Share price
- ₹125.58
- Market cap
- ₹6,881 Cr
- Revenue (annual)
- ₹1,806 Cr
- Net profit (annual)
- ₹94.88 Cr
- P/E (TTM)
- 36.5×Sector 46.1×
- Promoter holding
- 35.65%+0.00% QoQ
- FII holding
- 3.43%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Morepen Laboratories Ltd
All →Morepen Laboratories Management Change
Morepen Laboratories announced promotions effective 27 October 2026 for two senior management personnel. Charanjeet Chitakara moves to Assistant Vice President (Quality Control) and Vivan Prashar to Vice President (Projects & Engineering).
Morepen Laboratories Other Announcement
Morepen filed its Q2FY27 Monitoring Agency Report confirming Nil deviation in QIP proceeds utilization. The company spent ₹1.12 crore on modernization and expansion during the quarter.
Morepen Laboratories Results Update
Morepen hit record Q2 FY27 revenue up 81% and EBITDA up 273%, driven by CDMO scale-up. H1 EBITDA reached ₹220 Cr; API+CDMO capacity now 614 KL.
- API + CDMO manufacturing capacity
- 614 KL
Morepen Laboratories Q2 FY27 Results: Net Profit ₹88.9 Cr, Up 117.4% YoY
Morepen Laboratories Ltd reported revenue from operations of ₹746.5 Cr (+81.4% YoY) and net profit of ₹88.9 Cr (+117.4% YoY) for Q2 FY27.
- Key figure
- Net profit ₹88.9 Cr · +117.4% YoY
Morepen Laboratories Board Meeting Date
Morepen Laboratories Limited announced a board meeting scheduled for October 27, 2026. The meeting will consider and approve the financial results for the quarter ended September 30, 2026.
Morepen Laboratories Legal & Regulatory
The High Court of Himachal Pradesh quashed a GST show cause notice against Morepen Laboratories, resolving a demand of ₹117.94 Crore in the company's favour.
- Value
- ₹117.9 Cr